ClinicalTrials.gg
RecruitingNCT05444088Updated Jun 21, 2024

Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma

A Phase 1/2 interventional study of Adebrelimab and Bevacizumab in Advanced Hepatocellular Carcinoma, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-06-21.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing adebrelimab in Carcinoma, Hepatocellular — 12 open to participants now, 12 under way, 1 of them phase 3. adebrelimab · Carcinoma, Hepatocellular.

Planned enrollment
3rd of 13
129 · median 52
Started
2022
the only one that year
Phase 1/2
3 of 13
3 open now
Primary completion
2026-06
later than 2 of 11 live
Registered
1st of 13
by date
Lead sponsor
2 of 13
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Among the 13 studies testing adebrelimab in Carcinoma, Hepatocellular, this one is the 3rd largest by planned enrollment, is the only one that started in 2022, is one of 3 in phase 1/2, reaches primary completion later than 2 of the 11 other live ones, and was the 1st registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

12 of the 13 studies testing adebrelimab in Carcinoma, Hepatocellular are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

About adebrelimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing adebrelimab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

To evaluate the tolerability and safety of SHR-8068 in combination with Adebrelimab and Bevacizumab in subjects with advanced HCC; To evaluate the efficacy of SHR-8068 in combination with Adebrelimab and Bevacizumab in subjects with advanced HCC.

03

Conditions studied

  • Advanced Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18\~75 years old, both male and female;
  2. Stage 1: diagnosed, incurable advanced HCC subjects who have failed standard treatment or were unwilling to accept standard treatment;
  3. Stage 2: pathologically diagnosed, incurable advanced HCC subjects, who have no prior immunotherapy, no more than 1 line of previous system treatment;
  4. At least one based on v1.1 criteria;
  5. Barcelona clinic liver cancer: Stage B or C;
  6. PS score: 0-1 points;
  7. score: ≤ 7;
  8. Expected survival period ≥ 3 months;
  9. Adequate organ function.

Exclusion criteria

Exclusion Criteria:

  1. Fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma or mixed cholangiocarcinoma / hepatocellular carcinoma;
  2. Patients with any active, known or suspected disorder;
  3. Systemic treatment with or other within 1 month before the first dose;
  4. With known severe allergic reactions to any other monoclonal antibodies;
  5. Patients with known or hepatic encephalopathy;
  6. Patients with liver tumor burden greater than 50% of total liver in volume, or patients who have previously undergone liver transplantation;
  7. Patients with symptomatic ascites or pleural effusion requiring paracentesis and drainage, or patients who have undergone ascites or pleural effusion drainage within 2 weeks before the first dose;
  8. Patients with other currently or within the past 5 years;
  9. Patients with hypertension which cannot be well controlled by antihypertensives;
  10. Uncontrolled cardiac diseases or symptoms;
  11. Patients with other potential factors that may affect the study results.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
129 participants (estimated)

Study arms

  • Experimental
    Adebrelimab in combination with Bevacizumab

    Drug: Adebrelimab · Drug: Bevacizumab

  • Experimental
    Adebrelimab in combination with Bevacizumab and SHR-8068 RP2D1

    Drug: Adebrelimab · Drug: Bevacizumab · Drug: SHR-8068

  • Experimental
    Adebrelimab in combination with Bevacizumab and SHR-8068 RP2D2

    Drug: Adebrelimab · Drug: Bevacizumab · Drug: SHR-8068

Interventions

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicity

    Time frame: The observation period is 21 days after the first dose

  2. Incidence and severity of grade ≥3 drug-related adverse events and serious adverse events of the two-drug or three-drug combination

    Time frame: The observation period is from the time when all informed subjects signed the informed consent to the end of the safety follow-up period, up to 2 years

  3. Objective Response Rate

    determined using RECIST v1.1 criteria, defined as best overall response (complete or partial response) across all assessment time points

    Time frame: At the time point of every 6 or 9 weeks, up to 2 years

Secondary outcomes

  1. Disease Control Rate, determined using RECIST v1.1 criteria

    Time frame: At the time point of every 6 or 9 weeks, up to 2 years

  2. Progression-Free-Survival assessed by investigator

    Time frame: up to 2 years]

07

Study locations

1 of 1 sites recruiting
  • Anhui Provincial Hospital Ethics Commitee
    Hefei, Anhui 230000, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Jun 2026, 46 months after the start.

Of 72 industry-sponsored phase 1/2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 74. This study's planned 46 months is close to that.

Counting every sponsor, half of 136 studies reached it within 53 months; a quarter within 38 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2022
First posted
Jul 5, 2022
StartActual
Aug 2, 2022
Primary completionEst.
Jun 30, 2026
CompletionEst.
Jun 30, 2026
Last update
Jun 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05444088
Responsible party
Sponsor
First posted
Jul 5, 2022
Start date
Aug 2, 2022
Primary completion
Jun 30, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Jun 21, 2024

Study contacts

Xin Shi
Contact
xin.shi.xs3@hengrui.com
0518-82342973
Ying Sun
Contact
ying.sun.ys1@hengrui.com
0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adebrelimab · Bevacizumab

Start the discussion